April 30, 2021 | |||
Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2021 | |||
[Japanese GAAP] | |||
Company name: | NIHON CHOUZAI Co., Ltd. | Listing: Tokyo Stock Exchange, First Section | |
Stock code: | 3341 | URL: https://www.nicho.co.jp | |
Representative: | Yosuke Mitsuhara, President & CEO | ||
Contact: | Kazunori Ogi, Director, General Manager of Finance Department | Tel: +81-(0)3-6810-0800 | |
Scheduled date of Annual General Meeting of Shareholders: | June 24, 2021 | ||
Scheduled date of filing of Annual Securities Report: | June 25, 2021 | ||
Scheduled date of payment of dividend: | June 25, 2021 | ||
Preparation of supplementary materials for financial results: | Yes | ||
Holding of financial results meeting: | Yes (for institutional investors and analysts) |
Note: The original disclosure in Japanese was released on April 30, 2021 at 15:00 (GMT +9).
(All amounts are rounded down to the nearest million yen)
1. Consolidated Financial Results for the Fiscal Year Ended March 31, 2021 (April 1, 2020 - March 31, 2021)
(1) Consolidated results of operations | (Percentages represent year-on-year changes) | ||||||||||
Net sales | Operating profit | Ordinary profit | Profit attributable to | ||||||||
owners of parent | |||||||||||
Million yen | % | Million yen | % | Million yen | % | Million yen | % | ||||
Fiscal year ended Mar. 31, 2021 | 278,951 | 3.9 | 8,106 | 6.8 | 8,409 | 13.6 | 3,538 | (47.2) | |||
Fiscal year ended Mar. 31, 2020 | 268,520 | 9.3 | 7,593 | 12.8 | 7,405 | 21.8 | 6,697 | 76.7 |
Note: Comprehensive income (million yen) | FY3/21: 3,545 ( down 47.5%) | FY3/20: 6,756 (up 77.4%) | ||||
Net income per share | Diluted net income per | Return on equity | Ordinary profit on | Operating profit to net | ||
share | total assets | sales | ||||
Yen | Yen | % | % | % | ||
Fiscal year ended Mar. 31, 2021 | 118.01 | - | 7.3 | 4.5 | 2.9 | |
Fiscal year ended Mar. 31, 2020 | 223.33 | - | 15.2 | 4.1 | 2.8 | |
Reference: Equity in income (losses) of affiliates (million yen) | FY3/21: - | FY3/20: - |
Note: On April 1, 2020, the Company conducted a two-for-one stock split of common stock. Net income per share and Diluted net income per share have been calculated as if this stock split had taken place at the beginning of the previous fiscal year.
(2) Consolidated financial position
Total assets | Net assets | Equity ratio | Net assets per share | |||
Million yen | Million yen | % | Yen | |||
As of Mar. 31, 2021 | 186,262 | 49,868 | 26.8 | 1,663.01 | ||
As of Mar. 31, 2020 | 185,551 | 47,072 | 25.4 | 1,569.77 | ||
Reference: Shareholders' equity (million yen) | As of Mar. 31, 2021: | 49,868 | As of Mar. 31, 2020: | 47,072 |
Note: On April 1, 2020, the Company conducted a two-for-one stock split of common stock. Net assets per share has been calculated as if this stock split had taken place at the beginning of the previous fiscal year.
(3) Consolidated cash flows
Cash flows from operating | Cash flows from investing | Cash flows from financing | Cash and cash equivalents | |
activities | activities | activities | at end of period | |
Million yen | Million yen | Million yen | Million yen | |
Fiscal year ended Mar. 31, 2021 | 11,213 | (7,767) | (2,806) | 32,893 |
Fiscal year ended Mar. 31, 2020 | 13,192 | (2,731) | (7,955) | 32,254 |
2. Dividends
Dividend per share | Dividend payout | Dividend on net | |||||||
Total dividends | ratio | assets | |||||||
1Q-end | 2Q-end | 3Q-end | Year-end | Total | |||||
(consolidated) | (consolidated) | ||||||||
Yen | Yen | Yen | Yen | Yen | Million yen | % | % | ||
Fiscal year ended Mar. 31, 2020 | - | 25.00 | - | 25.00 | 50.00 | 749 | 11.2 | 1.7 | |
Fiscal year ended Mar. 31, 2021 | - | 12.50 | - | 12.50 | 25.00 | 749 | 21.2 | 1.5 | |
Fiscal year ending Mar. 31, 2022 | - | 12.50 | - | 12.50 | 25.00 | 14.5 | |||
(forecasts) | |||||||||
Note: On April 1, 2020, the Company conducted a two-for-one stock split of common stock. For the fiscal year ended March 31, 2020, the actual amounts of dividends prior to the stock split are presented.
3. Consolidated Forecast for the Fiscal Year Ending March 31, 2022 (April 1, 2021 - March 31, 2022)
(Percentages represent year-on-year changes)
Net sales | Operating profit | Ordinary profit | Profit attributable to | Net income per | |||||||
owners of parent | share | ||||||||||
Million yen | % | Million yen | % | Million yen | % | Million yen | % | Yen | |||
First half | 142,200 | 4.6 | 3,000 | 8.1 | 3,000 | 12.6 | 1,400 | (10.0) | 46.69 | ||
Full year | 293,400 | 5.2 | 9,200 | 13.5 | 9,100 | 8.2 | 5,100 | 44.1 | 170.07 |
Note: The impact of the spread of COVID-19 has taken into account some of the impact on sales that can be assumed at this time, but may fluctuate significantly depending on future trends.
- Notes
- Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in changes in scope of consolidation): None
- Changes in accounting policies and accounting-based estimates, and restatements
- Changes in accounting policies due to revisions in accounting standards, others: None
- Changes in accounting policies other than 1) above: None
- Changes in accounting-based estimates: None
- Restatements: None
- Number of outstanding shares (common stock shares)
- Number of shares outstanding at the end of period (including treasury shares)
As of Mar. 31, 2021: | 32,048,000 shares | As of Mar. 31, 2020: | 32,048,000 shares |
2) Number of treasury shares at the end of period | |||
As of Mar. 31, 2021: | 2,061,074 shares | As of Mar. 31, 2020: | 2,060,834 shares |
3) Average number of shares outstanding during the period | |||
Fiscal year ended Mar. 31, 2021: | 29,987,040 shares | Fiscal year ended Mar. 31, 2020: | 29,987,382 shares |
Note: On April 1, 2020, the Company conducted a two-for-one stock split of common stock. Number of shares outstanding at the end of the period, Number of treasury shares at the end of the period and Average number of shares outstanding during the period have been calculated as if this stock split had taken place at the beginning of the previous fiscal year.
(For reference) Summary of Non-consolidated Financial Results
1. Non-consolidated Financial Results for the Fiscal Year Ended March 31, 2021 (April 1, 2020 - March 31, 2021)
(1) Non-consolidated results of operations
Net sales | Operating profit | Ordinary profit | Profit | ||||||||
Million yen | % | Million yen | % | Million yen | % | Million yen | % | ||||
Fiscal year ended Mar. 31, 2021 | 233,619 | 4.4 | 5,326 | 15.7 | 7,018 | 32.9 | 3,499 | (25.1) | |||
Fiscal year ended Mar. 31, 2020 | 223,775 | 9.9 | 4,603 | 33.4 | 5,280 | 23.8 | 4,672 | 93.3 | |||
Net income per share | Diluted net income per share | ||||||||||
Yen | Yen | ||||||||||
Fiscal year ended Mar. 31, 2021 | 116.69 | - | |||||||||
Fiscal year ended Mar. 31, 2020 | 155.83 | - |
Note: On April 1, 2020, the Company conducted a two-for-one stock split of common stock. Net income per share and Diluted net income per share have been calculated as if this
stock split had taken place at the beginning of the previous fiscal year.
(2) Non-consolidated financial position
Total assets | Net assets | Equity ratio | Net assets per share | |||
Million yen | Million yen | % | Yen | |||
As of Mar. 31, 2021 | 145,540 | 37,657 | 25.9 | 1,255.80 | ||
As of Mar. 31, 2020 | 144,864 | 34,908 | 24.1 | 1,164.12 | ||
Reference: Shareholders' equity (million yen) | As of Mar. 31, 2021: | 37,657 | As of Mar. 31, 2020:34,908 |
Note: On April 1, 2020, the Company conducted a two-for-one stock split of common stock. Net assets per share has been calculated as if this stock split had taken place at the beginning of the previous fiscal year.
Note 1: This financial report is not subject to audit by certified public accountants or auditing firms.
Note 2: Cautionary statement with respect to forward-looking statements and other special items
(1) Note concerning forward-looking statements
Forecasts and other forward-looking statements in this document incorporate risks and uncertainties because these statements are based on Nihon Chouzai's judgments and assumptions using information that is currently available. These materials are not promises by Nihon Chouzai regarding future performance. Actual results may differ significantly from these forecasts for a number of reasons.
(2) How to view supplementary materials for financial results
The supplementary materials for financial results will be disclosed on TDNet, and will be posted on the Company's website.
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results | ||
Contents of Attachments | ||
1. Overview of Results of Operations | 2 | |
(1) | Results of Operations | 2 |
(2) | Financial Position | 4 |
(3) | Cash Flows | 4 |
(4) | Outlook | 5 |
2. Basic Approach to the Selection of Accounting Standards | 5 | |
3. Consolidated Financial Statements and Notes | 6 | |
(1) | Consolidated Balance Sheet | 6 |
(2) | Consolidated Statements of Income and Comprehensive Income | 8 |
(3) | Consolidated Statement of Changes in Equity | 10 |
(4) | Consolidated Statement of Cash Flows | 12 |
(5) | Notes to Consolidated Financial Statements | 14 |
(Going-concern Assumption) | 14 | |
(Segment and Other Information) | 14 | |
(Per Share Information) | 19 | |
(Subsequent Events) | 19 |
1
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
1. Overview of Results of Operations
(1) Results of Operations
During the fiscal year ended March 31, 2021, Japan's economy remained unpredictable. COVID -19 continued to affect the economy, with no indication of when the spread of the virus might be contained, as illustrated by the repeated state of emergency declarations.
Under these economic circumstances, our Group took exhaustive infection prevention measu res in each of our dispensing pharmacies while continuing to offer high -quality medical care, maintaining a firm commitment to our mission as a medical institution responsible for local medical care. We have also implemented cost -cutting measures throughout the Group.
In the Dispensing Pharmacy Business, when the rules were changed in September 2020 to allow online medication guidance across the country, the Group immediately seized on that opportunity by launching the Nihon Chouzai Online Pharmacy Service, our independently developed online medication guidance system. By teaming up with major online healthcare service providers, we assembled a seamless package of online healthcare and online medication guidance. In addition, we took ambitious steps to provide new medical services to meet patient needs. Such new initiatives included experiments with the use of drones to fly in medicine deliveries to remote islands, delivery of prescriptions using home delivery lockers, and trial operation of same -day medicine delivery using motorcycle couriers.
We sprang to action on online insurance coverage confirmation as well. Starting in March 2021, people in Japan are able to use their "My Number" social security and taxation identification cards as an alternative to hea lth insurance cards, which allows hospitals to confirm patients' eligibility for insurance coverage. We responded right away by leveraging the centralized information base of our independently developed dispensing system to expand pre-launch operations throughout the country. In addition to improving user-friendliness for patients, this also contributes to fine-tuned medication guidance through means such as centralized and continuous management of medication information, which is the duty of each patient's regular pharmacist. By promoting the use of information and communication technologies (ICT) in medical information, we are working to provide higher quality medical care.
We are also engaged in activities to contribute to local communities through healthcare. Our Health Check Stations provide support for the health of local residents, and we begin offering the "SocRTes" social PCR testing at select Health Check Station locations to help contain the spread of COVID -19 and stimulate economic activity. We have also obtained Certified Nutrition Care Station certification from the Japan Dietetic Association, and prepared to pour our resources into advancing the health of local residents.
In the Pharmaceutical Manufacturing and Sales Business, even as the pharma ceuticals market overall has been shrinking due to the impacts of COVID -19, we expanded our catalog of in-house manufactured product offerings through aggressive R&D, and saw particularly robust sales in newly NHI listed items brought to market since December 2019. The business consequently provided a major boost to Group earnings.
In the Medical Professional Staffing and Placement Business, we expanded our business with our November 2020 acquisition of Workers Doctors Inc., a company that provides industri al physician services, largely in the Tokyo metropolitan area. Industrial physicians are growing in importance as corporations push for "healthy business administration," and we will work to generate new synergies by leveraging Workers Doctors' expertise in industrial physician services and our Group's nationwide sales force and record of successful doctor placements .
For the fiscal year ended March 31, 2021, we posted net sales of 278,951 million yen (+3.9% YoY), operating profit of 8,106 million yen (+6.8% YoY), ordinary profit of 8,409 million yen (+13.6% YoY), and profit attributable to owners of parent of 3,538 million yen (-47.2% YoY).
Our Group remains committed to maintaining our prime medical care provision structure while continuing to implement infection prevention measures.
Segment-specific earnings are as indicated below.
2
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
1) Dispensing Pharmacy Business
In the fiscal year under review, the Dispensing Pharmacy Business reported net sales of 244,072 million yen (+5.7% YoY) and operating profit of 10,585 million yen (+8.2% YoY).
The total number of pharmacies at the end of March 2021 came to 670 (including one merchandise store) as a result of 29 openings and 9 closures during the fiscal year.
Sales and profits, though hit by the ongoing pandemic -driven decrease in prescriptions, both rose thanks to the effect of store openings in the previous fiscal year, higher prescription unit prices with the increase in long-term prescriptions, and cost-cutting efforts throughout the Group.
Generic drugs represented 89.3% of the Company's total pharmaceutical usage in volume terms as of the end of March, 2021 (the Japanese government had targeted the generic drug ratio of 80% by the end of September 2020). Pharmacies providing at-home medical care service came to a favorable 90.8% at the Company (ratio of pharmacies providing 12 or more at-home care visits per year).
2) Pharmaceutical Manufacturing and Sales Business
In the fiscal year under review, the Pharmaceutical Manufacturing and Sales Business reported net sales of 45,699 million yen (+6.1% YoY) and operating profit of 2,350 million yen (+80.6% YoY).
Despite cuts in existing product prices due to NHI pricing revisions in April 2020, net sales increased thanks to robust sales of products newly listed in December 2019, June 2020 and December 2020. Operating profit was buoyed by cost-cutting undertakings as well as a sales stance focused on profitability, and higher margins from expanded sales of in-house manufactured products, including new listed drugs.
The Company had launched 21 newly listed items during the fiscal year under review, bringing the total number of listed products to 677 at fiscal year-end (including 2 OTC drugs).
3) Medical Professional Staffing and Placement Business
In the fiscal year under review, the Medical Professional Staffing and Placement Business generated net sal es of 8,393 million yen (-34.0% YoY) and operating profit of 712 million yen (-61.5% YoY).
We continued our shift from pharmacist temporary staffing to permanent placement to reflect changing demand in personnel markets due to the start of the family pharmacist system, but net sales declined due to the ongoing impact of increased pandemic-related constraints on staff dispatchment. Lower sales from the pharmacist dispatchment business led to a sharp decline in operating profit despite the robust performance in the placement b usiness for both physicians and pharmacists.
3
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
(2) Financial Position
Total assets as of the end of March 2021 were 186,262 million yen, up 711 million yen (+0.4%), compared to 185,551 million yen at the end of the previous consolidated fiscal year. This is mainly due to increases in Raw materials and supplies and Construction in progress.
Total liabilities were 136,394 million yen, down 2,084 million yen (-1.5%) compared to 138,478 million yen at the end of the previous consolidated fiscal year. This is mainly due to increased current liabilities such as accounts payable and decreased Income taxes payable.
Total net assets were 49,868 million yen, up 2,795 million yen (+5.9%) compared to 47,072 million yen at the end of the previous consolidated fiscal year. As a result, our equity ratio is 26.8%
(3) Cash Flows
There was a net increase of 639 million yen in cash and cash equivalents from the end of March 2020 to 32,893 million yen at the end of March 2021.
Net cash provided by operating activities was 11,213 million yen, a decrease of 1,979 million yen from one year earlier. Major income factors include income of 6,483 million yen from profit before income taxes. Conversely, major expenditure factors include expenditures of 6,716 million yen in income tax paid.
Net cash used in investing activities 7,767 million yen, an increase of 5,035 million yen. Major expenditure factors include expenditures of 5,955 million yen for the purchase of property, plant and equipment. This is mainly comprised of investments for new store opening in the dispensing pharmacy business and capital investments in the pharmaceutical manufacturing and sales business.
Net cash used in financing activities 2,806 million yen, a decrease of 5,149 million yen. Major income factors include income of 8,000 million yen from long-term loans payable. Conversely, major expenditure factors include expenditures of 9,406 million yen in repayments of long-term loans payable.
Trends in cash flow indicators
FY3/17 | FY3/18 | FY3/19 | FY3/20 | FY3/21 | |
Shareholders' equity ratio (%) | 20.4 | 22.2 | 23.0 | 25.4 | 26.8 |
Shareholders' equity ratio based on | 33.9 | 28.7 | 31.5 | 26.7 | 28.7 |
market prices (%) | |||||
Cash flows to debt ratio (years) | - | 3.8 | 6.0 | 5.6 | 6.5 |
Interest coverage ratio (times) | - | 37.1 | 25.8 | 34.9 | 35.1 |
Note: The above figures are calculated as follows.
Shareholders' equity ratio: Shareholders' equity / Total assets
Shareholders' equity ratio based on market prices: Market capitalization / Total assets
Cash flows to debt ratio: Interest-bearing debts / Operating cash flows
Interest coverage ratio: Operating cash flows / Interest payments
- All indices are calculated based on consolidated figures.
- Market capitalization is calculated by multiplying the listed share price at the end of period by the number of shares outstanding (net of treasury shares) at the end of period.
- Operating cash flows are calculated using the figures for "Net cash provided by (used in) operating activities" in the consolidated statement of cash flows. Interest-bearing debts include all debts on the consolidated balance sheet that incur interest. Interest payments are calculated using the figures for "Interest expenses paid" in the consolidated statement of cash flows. Cash flows to debt ratio and interest coverage ratio for FY3/17 are not presented because operating cash flows were negative.
4
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
(4) Outlook
For the fiscal year ending on March 31, 2022, Nihon Chouzai forecasts consolidated net sales of 293,400 million yen (+5.2% YoY), operating profit of 9,200 million yen (+13.5% YoY), ordinary profit of 9,100 million yen (+8.2% YoY), and profit attributable to owners of parent of 5,100 million yen (+44.1% YoY).
The dispensing pharmacy and pharmaceutical industries are facing a tougher business environment. With the promulgation of the Act for Partial Amendment to the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Revised Pharmaceutical and Medical Devices Act), August 2021 will see the start of prefectural governor certification of pharmacies with specialized functions to enable patients to select pharmacies that best match their needs. Under this system, the dispensing pharmacies will be classified as "regional cooperation pharmacies" (those capable of partnering with other medical institutions on medication information, including at-home medical care and hospitalization/discharge), "specialized medical institutions cooperation pharmacies" (which requires the ability to handle high -level pharmacological management and advanced expertise in oncology and other areas), and other pharmacies that only perform simple dispensing. The system will therefore require the kind of pharmacies that are capable to meeting patients ' needs to a much higher degree. In addition, from April 2021, NHI drug pricing revisions switched from every other year to annual revision .
Given such business conditions, in our core Dispensing Pharmacies Business, our Group will work to develop highly user-friendly pharmacies and cultivate pharmacists with advanced expertise so as to provide the kind of pharmacies the Japanese government seeks, and deliver high -quality medical care services to patients through our certified specialized medical institutions cooperation pharmacies and regional cooperation pharmacies. In our Pharmaceutical Manufacturing and Sales Business, we will utilize synergies with other group businesses, which is a key strength of the Nihon Chouzai Group, as well as invest in R&D to expand our catalog of in -house manufactured product offerings, including newly listed drugs, and improve profitability. In our Medical Professional Staffing and Placement Business, we will work to further fortify the business of placing pharmacists, physicians, and other medical professionals, as well as operate nationwide industrial physician services, primarily through Workers Doctors Inc., and thereby further expand our physicians busi ness.
In addition, we will take the lead on measures to enhance user friendliness and pharmacy functions with online medication guidance and online insurance coverage confirmation, as well as conduct Group business administration by making full use of our acumen in next-generation dispensing systems development and other information and communication technologies (ICT).
Regarding the impact of COVID-19 on earnings for the fiscal year ending on March 31, 2022, our current earnings forecasts are premised on the assumption that the business environment in second half of the fiscal year ended March 31, 2021, will persist throughout the year, but should circumstances change substantially, we will disclose any necessary revisions to earnings forecasts as soon as possible.
2. Basic Approach to the Selection of Accounting Standards
The Nihon Chouzai Group will continue to prepare consolidated financial statements using Japanese accounting standards for the time being to permit comparisons with prior years and with the financial data of other companies.
We will take suitable actions with regard to the application of the International Financial Reporting Standards (IFRS) by taking into account associated factors in Japan and other countries.
5
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
3. Consolidated Financial Statements and Notes
(1) Consolidated Balance Sheet
(Millions of yen) | |||
FY3/20 | FY3/21 | ||
(As of Mar. 31, 2020) | (As of Mar. 31, 2021) | ||
Assets | |||
Current assets | |||
Cash and deposits | 32,254 | 32,893 | |
Notes receivable-trade | 181 | 80 | |
Accounts receivable-trade | 20,587 | 21,050 | |
Electronically recorded monetary claims-operating | 1,080 | 831 | |
Merchandise and finished goods | 22,988 | 23,139 | |
Work in process | 1,541 | 1,413 | |
Raw materials and supplies | 5,431 | 6,174 | |
Other | 3,354 | 3,668 | |
Allowance for doubtful accounts | (6) | (6) | |
Total current assets | 87,414 | 89,246 | |
Non-current assets | |||
Property, plant and equipment | |||
Buildings and structures | 53,112 | 53,669 | |
Accumulated depreciation | (22,189) | (24,102) | |
Buildings and structures, net | 30,922 | 29,566 | |
Machinery, equipment and vehicles | 20,944 | 20,960 | |
Accumulated depreciation | (5,860) | (6,927) | |
Machinery, equipment and vehicles, net | 15,084 | 14,033 | |
Land | 14,653 | 14,198 | |
Leased assets | 2,883 | 2,789 | |
Accumulated depreciation | (2,228) | (1,592) | |
Leased assets, net | 655 | 1,196 | |
Construction in progress | 967 | 1,649 | |
Other | 17,947 | 19,595 | |
Accumulated depreciation | (14,148) | (15,455) | |
Other, net | 3,798 | 4,140 | |
Total property, plant and equipment | 66,082 | 64,785 | |
Intangible assets | |||
Goodwill | 16,994 | 16,508 | |
Other | 2,431 | 2,443 | |
Total intangible assets | 19,425 | 18,952 | |
Investments and other assets | |||
Investment securities | 16 | 16 | |
Long-term loans receivable | 703 | 635 | |
Leasehold and guarantee deposits | 7,765 | 8,288 | |
Deferred tax assets | 3,090 | 3,368 | |
Other | 1,052 | 967 | |
Total investments and other assets | 12,628 | 13,277 | |
Total non-current assets | 98,137 | 97,015 | |
Total assets | 185,551 | 186,262 | |
6
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
(Millions of yen)
FY3/20 | FY3/21 | ||
(As of Mar. 31, 2020) | (As of Mar. 31, 2021) | ||
Liabilities | |||
Current liabilities | |||
Accounts payable-trade | 42,659 | 44,044 | |
Electronically recorded obligations-operating | 3,131 | 2,742 | |
Short-term loans payable | 100 | - | |
Current portion of long-term loans payable | 9,406 | 27,966 | |
Lease obligations | 82 | 139 | |
Income taxes payable | 4,132 | 884 | |
Provision for bonuses | 3,318 | 3,602 | |
Provision for bonuses for directors (and other officers) | 76 | 46 | |
Asset retirement obligations | 9 | 80 | |
Other | 7,191 | 8,214 | |
Total current liabilities | 70,107 | 87,720 | |
Non-current liabilities | |||
Long-term loans payable | 62,963 | 42,997 | |
Lease obligations | 479 | 1,229 | |
Long-term accounts payable-installment purchase | 886 | 424 | |
Provision for retirement benefits for directors (and | 474 | 199 | |
other officers) | |||
Retirement benefit liability | 1,957 | 2,153 | |
Asset retirement obligations | 1,289 | 1,336 | |
Other | 318 | 332 | |
Total non-current liabilities | 68,370 | 48,673 | |
Total liabilities | 138,478 | 136,394 | |
Net assets | |||
Shareholders' equity | |||
Capital stock | 3,953 | 3,953 | |
Capital surplus | 10,926 | 10,926 | |
Retained earnings | 35,762 | 38,551 | |
Treasury shares | (3,499) | (3,500) | |
Total shareholders' equity | 47,143 | 49,931 | |
Accumulated other comprehensive income | |||
Remeasurements of defined benefit plans | (70) | (63) | |
Total accumulated other comprehensive income | (70) | (63) | |
Total net assets | 47,072 | 49,868 | |
Total liabilities and net assets | 185,551 | 186,262 | |
7
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
-
Consolidated Statements of Income and Comprehensive Income
(Consolidated Statement of Income)
(Millions of yen) | |||
FY3/20 | FY3/21 | ||
(Apr. 1, 2019 - Mar. 31, 2020) | (Apr. 1, 2020 - Mar. 31, 2021) | ||
Net sales | 268,520 | 278,951 | |
Cost of sales | 222,147 | 229,577 | |
Gross profit | 46,372 | 49,374 | |
Selling, general and administrative expenses | 38,779 | 41,267 | |
Operating profit | 7,593 | 8,106 | |
Non-operating income | |||
Interest income | 0 | 0 | |
Commission income | 41 | 36 | |
Rent income | 426 | 446 | |
Compensation income | 80 | 51 | |
Insurance claim income | 88 | 34 | |
Subsidy income | 75 | 655 | |
Other | 165 | 183 | |
Total non-operating income | 878 | 1,408 | |
Non-operating expenses | |||
Interest expenses | 364 | 314 | |
Commission expenses | 20 | 10 | |
Rent expenses | 336 | 331 | |
Loss on retirement of non-current assets | 98 | 261 | |
Other | 246 | 188 | |
Total non-operating expenses | 1,066 | 1,105 | |
Ordinary profit | 7,405 | 8,409 | |
Extraordinary income | |||
Gain on sales of non-current assets | 6,662 | 398 | |
Gain on sale of businesses | 34 | - | |
Reversal of provision for retirement benefits for | 634 | - | |
directors (and other officers) | |||
Total extraordinary income | 7,332 | 398 | |
Extraordinary losses | |||
Loss on abandonment of non-current assets | 187 | 375 | |
Loss on sales of non-current assets | 1 | 1 | |
Impairment loss | 2,663 | 1,920 | |
Loss on sales of investment securities | 0 | - | |
Loss on disaster | - | 27 | |
Total extraordinary losses | 2,852 | 2,324 | |
Profit before income taxes | 11,885 | 6,483 | |
Income taxes-current | 5,544 | 3,218 | |
Income taxes-deferred | (357) | (273) | |
Total income taxes | 5,186 | 2,945 | |
Profit | 6,698 | 3,538 | |
Profit attributable to non-controlling interests | 1 | - | |
Profit attributable to owners of parent | 6,697 | 3,538 | |
8
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
(Consolidated Statement of Comprehensive Income)
(Millions of yen) | ||
FY3/20 | FY3/21 | |
(Apr. 1, 2019 - Mar. 31, 2020) | (Apr. 1, 2020 - Mar. 31, 2021) | |
Profit | 6,698 | 3,538 |
Other comprehensive income |
Valuation difference on available-for-sale securities Remeasurements of defined benefit plans, net of tax Total other comprehensive income
Comprehensive income
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
Comprehensive income attributable to non- controlling interests
(0) | - |
57 | 6 |
57 | 6 |
6,756 | 3,545 |
6,754 | 3,545 |
1 | - |
9
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
-
Consolidated Statement of Changes in Equity
FY3/19 (Apr. 1, 2019 - Mar. 31, 2020)
(Millions of yen) | |||||||||||
Shareholders' equity | |||||||||||
Capital stock | Capital surplus | Retained | Treasury shares | Total shareholders' | |||||||
earnings | equity | ||||||||||
Balance at beginning of current | 3,953 | 10,926 | 29,815 | (3,498) | 41,196 | ||||||
period | |||||||||||
Changes of items during period | |||||||||||
Dividends of surplus | (749) | (749) | |||||||||
Profit attributable to owners of | 6,697 | 6,697 | |||||||||
parent | |||||||||||
Purchase of treasury shares | (0) | (0) | |||||||||
Net changes of items other | |||||||||||
than shareholders' equity | |||||||||||
Total changes of items during | - | - | 5,947 | (0) | 5,946 | ||||||
period | |||||||||||
Balance at end of current period | 3,953 | 10,926 | 35,762 | (3,499) | 47,143 | ||||||
Accumulated other comprehensive income | |||||||||||
Valuation | Remeasurements | Total accumulated | Non-controlling | Total net | |||||||
difference on | of defined benefit | other | interests | assets | |||||||
available-for-sale | comprehensive | ||||||||||
securities | plans | income | |||||||||
Balance at beginning of current | 0 | (127) | (127) | 4 | 41,073 | ||||||
period | |||||||||||
Changes of items during period | |||||||||||
Dividends of surplus | (749) | ||||||||||
Profit attributable to owners | 6,697 | ||||||||||
of parent | |||||||||||
Purchase of treasury shares | (0) | ||||||||||
Net changes of items other | (0) | 57 | 57 | (4) | 52 | ||||||
than shareholders' equity | |||||||||||
Total changes of items during | (0) | 57 | 57 | (4) | 5,999 | ||||||
period | |||||||||||
Balance at end of current | - | (70) | (70) | - | 47,072 | ||||||
period | |||||||||||
10
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
FY3/20 (Apr. 1, 2020 - Mar. 31, 2021)
(Millions of yen) | |||||||||||
Shareholders' equity | |||||||||||
Capital stock | Capital surplus | Retained | Treasury shares | Total shareholders' | |||||||
earnings | equity | ||||||||||
Balance at beginning of current | 3,953 | 10,926 | 35,762 | (3,499) | 47,143 | ||||||
period | |||||||||||
Changes of items during period | |||||||||||
Dividends of surplus | (749) | (749) | |||||||||
Profit attributable to owners of | 3,538 | 3,538 | |||||||||
parent | |||||||||||
Purchase of treasury shares | (0) | (0) | |||||||||
Net changes of items other | |||||||||||
than shareholders' equity | |||||||||||
Total changes of items during | - | - | 2,789 | (0) | 2,788 | ||||||
period | |||||||||||
Balance at end of current period | 3,953 | 10,926 | 38,551 | (3,500) | 49,931 | ||||||
Accumulated other comprehensive income | |||||||||||
Valuation | Remeasurements | Total accumulated | Non-controlling | Total net | |||||||
difference on | of defined benefit | other | interests | assets | |||||||
available-for-sale | comprehensive | ||||||||||
securities | plans | income | |||||||||
Balance at beginning of current | - | (70) | (70) | - | 47,072 | ||||||
period | |||||||||||
Changes of items during period | |||||||||||
Dividends of surplus | (749) | ||||||||||
Profit attributable to owners | 3,538 | ||||||||||
of parent | |||||||||||
Purchase of treasury shares | (0) | ||||||||||
Net changes of items other | 6 | 6 | 6 | ||||||||
than shareholders' equity | |||||||||||
Total changes of items during | - | 6 | 6 | - | 2,795 | ||||||
period | |||||||||||
Balance at end of current | - | (63) | (63) | - | 49,868 | ||||||
period | |||||||||||
11
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
(4) Consolidated Statement of Cash Flows
(Millions of yen) | |||
FY3/20 | FY3/21 | ||
(Apr. 1, 2019 - Mar. 31, 2020) (Apr. 1, 2020 - Mar. 31, 2021) | |||
Cash flows from operating activities | |||
Profit before income taxes | 11,885 | 6,483 | |
Depreciation | 6,316 | 6,416 | |
Amortization of long-term prepaid expenses | 169 | 154 | |
Impairment loss | 2,663 | 1,920 | |
Loss on disaster | - | 27 | |
Amortization of goodwill | 1,581 | 1,763 | |
Increase (decrease) in allowance for doubtful accounts | 0 | 0 | |
Increase (decrease) in provision for bonuses | 283 | 282 | |
Increase (decrease) in provision for bonuses for directors | (10) | (30) | |
(and other officers) | |||
Increase (decrease) in retirement benefit liability | 122 | 193 | |
Increase (decrease) in provision for retirement benefits | (726) | (275) | |
for directors (and other officers) | |||
Interest and dividend income | (0) | (1) | |
Interest expenses | 364 | 314 | |
Loss (gain) on sales of non-current assets | (6,661) | (396) | |
Loss (gain) on sales of investment securities | 0 | - | |
Loss (gain) on sale of businesses | (34) | - | |
Decrease (increase) in notes and accounts receivable- | (2,902) | (20) | |
trade | |||
Decrease (increase) in inventories | 74 | (694) | |
Increase (decrease) in notes and accounts payable-trade | 3,486 | 1,250 | |
Decrease (increase) in prepaid expenses | (149) | 128 | |
Increase (decrease) in accrued expenses | (51) | (248) | |
Decrease (increase) in accounts receivable-other | 422 | (456) | |
Increase (decrease) in accounts payable-other | (225) | 718 | |
Other, net | 6 | 717 | |
Subtotal | 16,615 | 18,246 | |
Interest and dividend income received | 0 | 1 | |
Interest expenses paid | (377) | (319) | |
Income taxes paid | (3,046) | (6,716) | |
Net cash provided by (used in) operating activities | 13,192 | 11,213 | |
Cash flows from investing activities | |||
Purchase of property, plant and equipment | (5,624) | (5,955) | |
Proceeds from sales of property, plant and equipment | 9,644 | 1,124 | |
Purchase of intangible assets | (606) | (573) | |
Proceeds from sales of investment securities | 0 | - | |
Increase in long-term prepaid expenses | (92) | (116) | |
Payments for acquisition of businesses | (771) | (907) | |
Proceeds from sale of businesses | 52 | - | |
Purchase of shares of subsidiaries resulting in change in | (5,057) | (823) | |
scope of consolidation | |||
Payment of loans receivable | (76) | (18) | |
Collection of loans receivable | 85 | 88 | |
Payments of leasehold and guarantee deposits | (626) | (769) | |
Proceeds from refund of leasehold and guarantee | 302 | 203 | |
deposits | |||
Other, net | 37 | (20) | |
Net cash provided by (used in) investing activities | (2,731) | (7,767) | |
12
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
(Millions of yen)
FY3/20 | FY3/21 | ||
(Apr. 1, 2019 - Mar. 31, 2020) (Apr. 1, 2020 - Mar. 31, 2021) | |||
Cash flows from financing activities | |||
Net increase (decrease) in short-term loans payable | 100 | (100) | |
Proceeds from long-term loans payable | 9,900 | 8,000 | |
Repayments of long-term loans payable | (16,261) | (9,406) | |
Repayments of lease obligations | (266) | (87) | |
Repayments of installment payables | (677) | (462) | |
Purchase of treasury shares | (0) | (0) | |
Cash dividends paid | (749) | (749) | |
Net cash provided by (used in) financing activities | (7,955) | (2,806) | |
Net increase (decrease) in cash and cash equivalents | 2,505 | 639 | |
Cash and cash equivalents at beginning of period | 29,749 | 32,254 | |
Cash and cash equivalents at end of period | 32,254 | 32,893 | |
13
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
-
Notes to Consolidated Financial Statements Going-concern Assumption
Not applicable.
Segment and Other Information
Segment information
1. Overview of reportable segments
Segments used for financial reporting are the Group's constituent units for which separate financial information is available and for which the Board of Directors performs periodic studies for the purposes of determining the allocation of resources and evaluating performance.
The Group consists of three business units: the dispensing pharmacy business, the pharmaceutical manufacturing and sales business, and the medical professional staffing and placement business. Each business unit determines its own comprehensive strategies and conducts its own business activities. Consequently, the Group has three reportable business segments: the dispensing pharmacy business, the pharmaceutical manufacturing and sales business, and the medical professional staffing and placement business.
The dispensing pharmacy business segment involves the operation of dispensing pharmacies. The pharmaceutical manufacturing and sales business segment involves manufacturing and sales activities that specialize mainly in generic drugs and other pharmaceuticals. The medical professional staffing and placement business segment involves the provision of a temporary staffing and placement services for pharmacists, physicians, nurses and other medical professionals.
2. Calculation method for net sales, profit or loss, assets, liabilities, and other items for each reportable segment
The accounting treatment methods for reportable segments are generally the same as those listed in "Basis of the Preparation of Consolidated Financial Statements."
Earnings for reportable segments are operating profit. Inter-segment sales and transfers are based on market prices.
14
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
3. Information related to net sales, profit or loss, assets, liabilities, and other items for each reportable segment FY3/20 (Apr. 1, 2019 - Mar. 31, 2020)
(Millions of yen) | ||||||
Reportable segment | Amounts shown | |||||
Medical | Adjustment | on consolidated | ||||
Dispensing | Pharmaceutical | professional | ||||
pharmacy | manufacturing | staffing and | Total | (Note 1) | financial | |
statements | ||||||
business | and sales business | placement | ||||
(Note 2) | ||||||
business | ||||||
Net sales | ||||||
(1) External sales | 230,989 | 24,899 | 12,631 | 268,520 | - | 268,520 |
(2) Inter-segment sales and | 12 | 18,172 | 90 | 18,275 | (18,275) | - |
transfers | ||||||
Total | 231,001 | 43,072 | 12,721 | 286,795 | (18,275) | 268,520 |
Segment profit (loss) | 9,785 | 1,301 | 1,851 | 12,938 | (5,345) | 7,593 |
Segment assets | 103,010 | 75,334 | 4,373 | 182,718 | 2,832 | 185,551 |
Other items | ||||||
Depreciation | 2,267 | 3,639 | 74 | 5,981 | 335 | 6,316 |
Amortization of goodwill | 1,483 | 97 | - | 1,581 | - | 1,581 |
Impairment loss | 2,390 | 272 | - | 2,663 | - | 2,663 |
Increase in property, plant | ||||||
and equipment and | 8,997 | 2,069 | 84 | 11,151 | 873 | 12,025 |
intangible assets |
Notes: 1. The above adjustments include the following items.
- The negative adjustment of 5,345 million yen to segment profit or loss includes a profit elimination of 20 million yen for inter-segment transactions and corporate expenses of minus 5,365 million yen. General and administrative expenses that do not belong to any reportable segment are the primary component of corporate expenses.
- The 2,832 million yen adjustment to segment assets includes a 28 million yen elimination for receivables associated with inter-segment transactions, a 166 million yen elimination for unrealized profit in inventories and a 3,027 million yen addition to corporate assets. Leasehold and guarantee deposits and land that do not belong to any reportable segment are the primary components of corporate assets.
- The 335 million yen adjustment of depreciation and the 873 million yen adjustment that is added to the increase in property, plant and equipment and intangible assets are for investments in corporate assets such as buildings.
2. Segment profit is adjusted to be consistent with operating profit shown on the consolidated statement of income.
15
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
FY3/21 (Apr. 1, 2020 - Mar. 31, 2021)
(Millions of yen) | ||||||
Reportable segment | Amounts shown | |||||
Medical | Adjustment | on consolidated | ||||
Dispensing | Pharmaceutical | professional | ||||
pharmacy | manufacturing | staffing and | Total | (Note 1) | financial | |
statements | ||||||
business | and sales business | placement | ||||
(Note 2) | ||||||
business | ||||||
Net sales | ||||||
(1) External sales | 244,072 | 26,526 | 8,352 | 278,951 | - | 278,951 |
(2) Inter-segment sales and | - | 19,172 | 41 | 19,213 | (19,213) | - |
transfers | ||||||
Total | 244,072 | 45,699 | 8,393 | 298,165 | (19,213) | 278,951 |
Segment profit (loss) | 10,585 | 2,350 | 712 | 13,648 | (5,542) | 8,106 |
Segment assets | 106,650 | 73,576 | 3,637 | 183,863 | 2,399 | 186,262 |
Other items | ||||||
Depreciation | 2,350 | 3,647 | 91 | 6,089 | 327 | 6,416 |
Amortization of goodwill | 1,660 | 97 | 4 | 1,763 | - | 1,763 |
Impairment loss | 807 | 1,112 | - | 1,920 | - | 1,920 |
Increase in property, plant | 6,289 | 2,701 | 98 | 9,089 | 402 | 9,492 |
and equipment and | ||||||
intangible assets |
Notes: 1. The above adjustments include the following items.
- The negative adjustment of 5,542 million yen to segment profit or loss includes a profit elimination of minus 34 million yen for inter-segment transactions and corporate expenses of minus 5,507 million yen. General and administrative expenses that do not belong to any reportable segment are the primary component of corporate expenses.
- The 2,399 million yen adjustment to segment assets includes a 12 million yen elimination for receivables associated with inter-segment transactions, a 206 million yen elimination for unrealized profit in inventories and a 2,617 million yen addition to corporate assets. Leasehold and guarantee deposits and land that do not belong to any reportable segment are the primary components of corporate assets.
- The 327 million yen adjustment of depreciation and the 402 million yen adjustment that is added to the increase in property, plant and equipment and intangible assets are for investments in corporate assets such as buildings.
2. Segment profit is adjusted to be consistent with operating profit shown on the consolidated statement of income.
16
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
Related information
FY3/20 (Apr. 1, 2019 - Mar. 31, 2020)
1. Information by product or service
Omitted because the same information is presented in segment information.
2. Information by region
(1) Net sales
Not applicable because there are no external sales outside Japan.
(2) Property, plant and equipment
Omitted because property, plant and equipment in Japan exceed 90% of property, plant and equipment on the consolidated balance sheet.
3. Information about specific customers
Omitted because no single external customer accounts for 10% or more of sales as shown on the consolidated statement of income.
FY3/21 (Apr. 1, 2020 - Mar. 31, 2021)
1. Information by product or service
Omitted because the same information is presented in segment information.
2. Information by region
(1) Net sales
Not applicable because there are no external sales outside Japan.
(2) Property, plant and equipment
Not applicable because there is no property, plant and equipment outside Japan.
3. Information about specific customers
Omitted because no single external customer accounts for 10% or more of sales as shown on the consoli dated statement of income.
17
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
Information related to impairment losses on non-current assets for each reportable segment
FY3/20 (Apr. 1, 2019 - Mar. 31, 2020)
Omitted because the same information is presented in segment information.
FY3/21 (Apr. 1, 2020 - Mar. 31, 2021)
Omitted because the same information is presented in segment information.
Information related to goodwill amortization and the unamortized balance for each reportable segment
FY3/20 (Apr. 1, 2019 - Mar. 31, 2020) | (Millions of yen) | |||
Dispensing pharmacy | Pharmaceutical | Medical professional | ||
manufacturing and | staffing and placement | Total | ||
business | ||||
sales business | business | |||
Unamortized balance at | 16,655 | 338 | - | 16,994 |
the end of current period | ||||
Note: Goodwill amortization is omitted because the same information is presented in segment information. | ||||
FY3/21 (Apr. 1, 2020 - Mar. 31, 2021) | (Millions of yen) | |||
Dispensing pharmacy | Pharmaceutical | Medical professional | ||
manufacturing and | staffing and placement | Total | ||
business | ||||
sales business | business | |||
Unamortized balance at | 16,093 | 240 | 174 | 16,508 |
the end of current period | ||||
Note: Goodwill amortization is omitted because the same information is presented in segment information. |
Information related to gain on bargain purchase for each reportable segment
FY3/20 (Apr. 1, 2019 - Mar. 31, 2020)
Not applicable.
FY3/21 (Apr. 1, 2020 - Mar. 31, 2021)
Not applicable.
18
Nihon Chouzai Co., Ltd. (3341) FY3/21 Financial Results
Per Share Information
(Yen) | |||
FY3/20 | FY3/21 | ||
(Apr. 1, 2019 - Mar. 31, 2020) | (Apr. 1, 2020 - Mar. 31, 2021) | ||
Net assets per share | 1,569.77 | 1,663.01 | |
Net income per share | 223.33 | 118.01 | |
Notes: 1. On April 1, 2020, the Company conducted a two-for-one stock split of common stock. Net assets per share and Net income per share have been calculated as if this stock split had taken place at the beginning of the previous fiscal year.
- Diluted net income per share is not presented since Nihon Chouzai has no outstanding dilutive securities.
- Basis for calculation of net assets per share is as follows.
FY3/20 | FY3/21 | |
(As of Mar. 31, 2020) | (As of Mar. 31, 2021) | |
Total net assets (Millions of yen) | 47,072 | 49,868 |
Deduction on total net assets (Millions of yen) | - | - |
Net assets applicable to common stock shares | 47,072 | 49,868 |
(Millions of yen) | ||
Number of common stock shares at end of period | ||
used in calculation of net assets per share | 29,987 | 29,986 |
(Thousand shares) |
Note: The number of common stock shares at the end of period that was used to calculate net assets per share is calculated after deducting treasury shares held in the Nihon Chouzai's account.
4. Basis for calculation of net income per share is as follows.
FY3/20 | FY3/21 | |
(Apr. 1, 2019 - Mar. 31, 2020) | (Apr. 1, 2020 - Mar. 31, 2021) | |
Profit attributable to owners of parent (Millions | 6,697 | 3,538 |
of yen) | ||
Amounts not available to common stock | - | - |
shareholders (Millions of yen) | ||
Profit attributable to owners of parent available to | 6,697 | 3,538 |
common stock shares (Millions of yen) | ||
Average number of common stock shares | 29,987 | 29,987 |
outstanding during the period (Thousand shares) | ||
Note: The average number of shares outstanding during the period that was used to calculate net income per share is calculated after deducting treasury shares held in the Nihon Chouzai's account.
Subsequent Events
Not applicable.
This summary report is solely a translation of "Kessan Tanshin" (in Japanese, including the attachments), which has been prepared in accordance with accounting principles and practices generally accepted in Japan, for the convenience of readers who prefer an English translation.
19
Attachments
- Original document
- Permalink
Disclaimer
NIHON CHOUZAI Co. Ltd. published this content on 30 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 April 2021 06:03:20 UTC.